数据来源：聚源 -40% 0% 40% 80% 120% 160% 2024-08 2024-12 2025-04 2025-08 艾迪药业 沪深300 相关研究报告 医药生物/生物制品 艾迪药业（688488.SH） 2025H1 营收净利双增长，HIV 治疗+预防全面布局 2025 年 08 月 29 日 投资评级：买入（维持） | 日期 | 2025/8/29 | | --- | --- | | 当前股价(元) | 17.36 | | 一年最高最低(元) | 18.45/6.58 | | 总市值(亿元) | 73.05 | | 流通市值(亿元) | 73.05 | | 总股本(亿股) | 4.21 | | 流通股本(亿股) | 4.21 | | 近 3 个月换手率(%) | 235.63 | 股价走势图 《期权激励助力新药放量，HIV 治疗+ 预防全面布局—公司信息更新报告》 -2025.7.2 《2025Q1 业绩扭亏为盈，抗艾新药有 望快速放量—公司信息更新报告》 -2025.4.30 《2024 年公司收入稳健增长，抗艾新 药持续放量—公司信息更新报告》 -2025.3.3 余汝意（分析师） 刘艺 ...

Core Viewpoint - The HIV drug market in China is experiencing rapid growth due to an increasing number of patients, expanding insurance coverage, and rising payment capabilities among the affected population, with a projected market size of 5.836 billion yuan in 2024, reflecting a year-on-year growth of 30.2% [1][16]. Industry Overview - HIV drugs are antiviral medications aimed at treating AIDS, which is caused by the human immunodeficiency virus (HIV) that attacks the immune system [2]. - As of the end of 2024, there are approximately 1.355 million reported living HIV/AIDS patients in China, with 749,800 being HIV-infected and 605,200 being AIDS patients [1][4]. Market Dynamics - The Chinese HIV drug market is expected to maintain a growth rate of over 20% from 2021 to 2024, driven by the increasing number of patients and the expansion of medical insurance coverage [16]. - The self-paid drug market is projected to reach 3.787 billion yuan in 2024, growing by 47.5% year-on-year, while the free drug market is expected to be 2.049 billion yuan, with a growth of 7% [18]. Competitive Landscape - Gilead and GSK dominate the Chinese HIV drug market, holding a combined market share of 90%, while local companies like Frontier Biopharma and Aidi Pharmaceutical have a smaller market presence of less than 10% [22]. Development Trends - Future research in the global HIV drug market will focus on developing new drugs with better efficacy and safety, exploring new drug targets, and investigating new treatment methods such as gene therapy and immunotherapy [24].